JP2024510500A - インドシアニングリーンの安定な処方物 - Google Patents

インドシアニングリーンの安定な処方物 Download PDF

Info

Publication number
JP2024510500A
JP2024510500A JP2023557348A JP2023557348A JP2024510500A JP 2024510500 A JP2024510500 A JP 2024510500A JP 2023557348 A JP2023557348 A JP 2023557348A JP 2023557348 A JP2023557348 A JP 2023557348A JP 2024510500 A JP2024510500 A JP 2024510500A
Authority
JP
Japan
Prior art keywords
indocyanine green
composition
compound
icg
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510500A5 (enExample
Inventor
ローラン・マリナ
サヤ・ババ
ロペ・ニコラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provepharm Life Solutions SA
Original Assignee
Provepharm Life Solutions SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provepharm Life Solutions SA filed Critical Provepharm Life Solutions SA
Publication of JP2024510500A publication Critical patent/JP2024510500A/ja
Publication of JP2024510500A5 publication Critical patent/JP2024510500A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023557348A 2021-03-17 2022-03-14 インドシアニングリーンの安定な処方物 Pending JP2024510500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305322 2021-03-17
EP21305322.6 2021-03-17
PCT/EP2022/056443 WO2022194731A1 (en) 2021-03-17 2022-03-14 Stable formulations of indocyanine green

Publications (2)

Publication Number Publication Date
JP2024510500A true JP2024510500A (ja) 2024-03-07
JP2024510500A5 JP2024510500A5 (enExample) 2025-02-06

Family

ID=75302474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557348A Pending JP2024510500A (ja) 2021-03-17 2022-03-14 インドシアニングリーンの安定な処方物

Country Status (8)

Country Link
US (1) US20240299549A1 (enExample)
EP (1) EP4308082A1 (enExample)
JP (1) JP2024510500A (enExample)
KR (1) KR20230157389A (enExample)
CN (1) CN117062597B (enExample)
BR (1) BR112023018955A2 (enExample)
MX (1) MX2023010927A (enExample)
WO (1) WO2022194731A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509260A (ja) * 1993-04-20 1996-10-01 マリンクロット・メディカル・インコーポレイテッド 電圧感受性染料の安定化
US20100181535A1 (en) * 2007-06-29 2010-07-22 Picoquant Gmbh The photostability and/or control of the fluorescence intensity of fluorescent dyes
JP2010539138A (ja) * 2007-09-14 2010-12-16 ミフェニオン ゲゼルシャフト ミット ベシュレンクテル ハフツング ナノ粒子製剤に基づく光学イメージング用診断物質
JP2024510501A (ja) * 2021-03-17 2024-03-07 プルーヴファーム・ライフ・ソリューションズ インドシアニングリーンの安定な処方物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710060B1 (fr) 1993-09-17 1995-11-17 Rech Biolog Et Procédé de préparation de benz[e]indoles substitués de pureté élevée et leurs sels alcalins.
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
CN103301482B (zh) 2013-06-27 2014-12-17 深圳先进技术研究院 两亲性三嵌段聚多肽载icg胶束及其制备方法
KR101774859B1 (ko) * 2014-11-27 2017-09-06 (주) 씨유스킨 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물
JP6623479B2 (ja) 2015-02-08 2019-12-25 トンリ・バイオメディカル・カンパニー・リミテッド 脂質ナノ粒子及びその使用
DK3383436T3 (da) 2015-12-01 2023-11-20 Dishman Carbogen Amcis Ltd Forbedret fremgangsmåde til fremstilling af indocyaningrønt
US20190337896A1 (en) 2018-05-02 2019-11-07 Biophore India Pharmaceuticals Pvt. Ltd. PROCESS FOR THE PREPARATION OF SODIUM 4-(2-((1E,3E,5E,7Z)-7-(1,1-DIMETHYL-3-(4-SULFONATOBUTYL)-1H-BENZO[e]INDOL-2(3H)-YLIDENE) HEPTA-1,3,5-TRIENYL)-1,1-DIMETHYL-1H-BENZO[e]INDOLIUM-3-YL) BUTANE-1-SULFONATE (INDOCYANINE GREEN)
WO2020240514A1 (en) 2019-05-30 2020-12-03 Leiutis Pharmaceuticals Pvt, Ltd. Stable formulations of indocyanine green

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509260A (ja) * 1993-04-20 1996-10-01 マリンクロット・メディカル・インコーポレイテッド 電圧感受性染料の安定化
US20100181535A1 (en) * 2007-06-29 2010-07-22 Picoquant Gmbh The photostability and/or control of the fluorescence intensity of fluorescent dyes
JP2010539138A (ja) * 2007-09-14 2010-12-16 ミフェニオン ゲゼルシャフト ミット ベシュレンクテル ハフツング ナノ粒子製剤に基づく光学イメージング用診断物質
JP2024510501A (ja) * 2021-03-17 2024-03-07 プルーヴファーム・ライフ・ソリューションズ インドシアニングリーンの安定な処方物

Also Published As

Publication number Publication date
WO2022194731A1 (en) 2022-09-22
KR20230157389A (ko) 2023-11-16
MX2023010927A (es) 2023-09-27
US20240299549A1 (en) 2024-09-12
CN117062597B (zh) 2025-12-02
EP4308082A1 (en) 2024-01-24
BR112023018955A2 (pt) 2023-10-17
CN117062597A (zh) 2023-11-14

Similar Documents

Publication Publication Date Title
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
US20240091198A1 (en) Aqueous composition comprising dantrolene
MXPA04005423A (es) Formulaciones farmaceuticas con derivado de platino.
JP2018531268A6 (ja) ダントロレンを含む水性組成物
CA2399405C (en) 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
JP7858686B2 (ja) 非経口カンナビノイド配合物およびその使用
WO2008023807A1 (fr) Composition pharmaceutique stabilisée
JP7400180B2 (ja) 非経口製剤及びその使用
JP7842776B2 (ja) インドシアニングリーンの安定な処方物
EP4308076B1 (en) Stable formulations of indocyanine green
EP3679925B1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
CN117062597B (zh) 稳定的吲哚菁绿制剂
MXPA94002884A (es) Composicion acuosa estable durante el almacenamiento y metodo para hacer la misma.
CA2486571C (en) Pharmaceutical composition
US20210100739A1 (en) Topical doxycycline composition
JP2026509786A (ja) グラム陽性菌血症の治療に使用するチカグレロール静脈内製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526